AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
